Profile
| Role | Insider |
|---|---|
| Notability | 20/100 |
Board memberships
- NeueHealth, Inc.
- Black Diamond Therapeutics, Inc.
- Adaptimmune Therapeutics PLC
- Arcellx, Inc.
Updated Jul 16, 2026
Behbahani Ali has filed 8 SEC Form 4 filings across 6 companies in the last 90 days — active on both sides. Lifetime open-market purchases: $15.00M. Lifetime open-market sales: $256K.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-06 | GLUE | Monte Rosa Therapeutics, Inc. | J — Other acquisition / disposition | 15.0K | $0.00 | |
| 2026-07-06 | GLUE | Monte Rosa Therapeutics, Inc. | J — Other acquisition / disposition | 15.0K | $0.00 | |
| 2026-07-06 | GLUE | Monte Rosa Therapeutics, Inc. | J — Other acquisition / disposition | 1.00M | $0.00 | |
| 2026-06-22 | BDTX | Black Diamond Therapeutics, Inc. | A — Grant or award | 9.0K | $1.66 | $15K |
| 2026-04-28 | ACLX | Arcellx, Inc. | J — Other acquisition / disposition | 2.7K | — | |
| 2026-04-28 | ACLX | Arcellx, Inc. | J — Other acquisition / disposition | 1.9K | — | |
| 2026-03-20 | BDTX | Black Diamond Therapeutics, Inc. | A — Grant or award | 6.9K | $2.15 | $15K |
| 2026-03-13 | KRRO | Korro Bio, Inc. | A — Grant or award | 207.1K | $11.11 | $2.30M |
| 2026-02-11 | SGP | SpyGlass Pharma, Inc. | J — Other acquisition / disposition | 402.3K | — | |
| 2026-02-11 | SGP | SpyGlass Pharma, Inc. | J — Other acquisition / disposition | 955.0K | — | |
| 2026-02-11 | SGP | SpyGlass Pharma, Inc. | P — Open-market purchase | 937.5K | $16.00 | $15.00M |
| 2026-02-11 | SGP | SpyGlass Pharma, Inc. | J — Other acquisition / disposition | 738.0K | — | |
| 2026-02-11 | SGP | SpyGlass Pharma, Inc. | J — Other acquisition / disposition | 1.37M | — | |
| 2026-02-11 | SGP | SpyGlass Pharma, Inc. | J — Other acquisition / disposition | 1.37M | — | |
| 2026-02-11 | SGP | SpyGlass Pharma, Inc. | J — Other acquisition / disposition | 1.62M | — | |
| 2025-10-02 | NEUE | NeueHealth, Inc. | D — Derivative transaction | 2.38M | — | |
| 2025-10-02 | NEUE | NeueHealth, Inc. | F — Tax withholding / forfeiture | 182 | $6.75 | $1K |
| 2025-10-02 | NEUE | NeueHealth, Inc. | M — Option exercise | 124.1K | $0.01 | $1K |
| 2025-10-02 | NEUE | NeueHealth, Inc. | S — Open-market sale | 900 | $6.75 | $6K |
| 2025-10-02 | NEUE | NeueHealth, Inc. | J — Other acquisition / disposition | 607.5K | $0.01 | $6K |
Behbahani Ali is a corporate insider — currently tracked as Insider of Monte Rosa Therapeutics, Inc. (GLUE). InsiderAlpha tracks every SEC Form 4 filing in real time.
8 primary Form 4 filings in the last 90 days, covering 6 companies.
Recorded transactions: 4 open-market purchases ($15.00M) and 6 open-market sales ($256K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Behbahani Ali profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.